SCHEMBL30983422

SCHEMBL30983422

CC1(Oc2ncnc3c2nc(-c2ccc(OCCOCC(=O)O)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.35
▸ PPARD Q03181 1/20 0.35
▸ CNR1 P21554 2/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ PIK3CD O00329 2/20 0.33
▸ MAOB P27338 1/20 0.33
▸ PLA2G2A P14555 3/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ PLA2G1B P04054 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ S1PR1 P21453 1/20 0.31
▸ S1PR5 Q9H228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268778 0.99 PPARG (0.35) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL31268983 0.96 PPARG (0.37) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL31269342 0.96 PPARG (0.38) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL31268992 0.94 CNR1 (0.35) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL30983976 0.92 MAOB (0.36) CNR1TLR7PIK3CDMAOBPLA2G2A
SCHEMBL30983880 0.92 MAOB (0.36) CNR1TLR7PIK3CDMAOBPLA2G2A
SCHEMBL31269035 0.92 CNR1 (0.36) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL30983523 0.91 PLA2G2A (0.38) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL30983451 0.91 PLA2G2A (0.38) PPARGPPARDCNR1PTGDR2TLR7
SCHEMBL31269376 0.90 PPARG (0.34) PPARGPPARDCNR1PTGDR2TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB PPARG 556/4885PPARD 2310/4885CNR1 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback